{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T04:25:58Z","timestamp":1770438358750,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,3,18]],"date-time":"2015-03-18T00:00:00Z","timestamp":1426636800000},"content-version":"vor","delay-in-days":382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007497","name":"Biosense Webster","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004374","name":"Medtronic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006279","name":"St. Jude Medical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006279","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jacc.2013.11.039","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T15:45:22Z","timestamp":1389195922000},"page":"982-988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"title":["Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation"],"prefix":"10.1016","volume":"63","author":[{"given":"Dhanunjaya","family":"Lakkireddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeruva Madhu","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Di Biase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay","family":"Vallakati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moussa C.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Santangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Gangireddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijay","family":"Swarup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadi","family":"Chalhoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donita","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudharani","family":"Bommana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier E.","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. David","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conor D.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwa","family":"Baheiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Ruskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Natale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.11.039_bib1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.hrthm.2011.12.016","volume":"4","author":"Calkins","year":"2012","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2013.11.039_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11886-010-0153-2","article-title":"Thromboembolic risk and anticoagulation strategies in patients undergoing catheter ablation for atrial fibrillation","volume":"1","author":"Viles-Gonzalez","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacc.2013.11.039_bib3","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.thromres.2009.11.031","article-title":"Peri-procedural anticoagulation in patients undergoing ablation for atrial fibrillation","volume":"126","author":"Vazquez","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2013.11.039_bib4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1540-8167.2008.01181.x","article-title":"Complications of catheter ablation for atrial fibrillation: incidence and predictors","volume":"19","author":"Spragg","year":"2008","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib5","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1161\/CIRCULATIONAHA.109.921320","article-title":"Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio","volume":"121","author":"Di Biase","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.039_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIRCEP.111.964916","article-title":"Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis","volume":"5","author":"Santangeli","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib7","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hrthm.2009.07.007","article-title":"Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy","volume":"6","author":"Hussein","year":"2009","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2013.11.039_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/europace\/eur038","article-title":"Catheter ablation of atrial fibrillation in patients with therapeutic oral anticoagulation treatment","volume":"13","author":"Hakalahti","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2013.11.039_bib9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1161\/CIRCULATIONAHA.107.727784","article-title":"Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period","volume":"116","author":"Wazni","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.039_bib10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1055\/s-0032-1333536","article-title":"The novel oral anticoagulants","volume":"39","author":"Rojas-Hernandez","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jacc.2013.11.039_bib11","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jacc.2011.12.014","article-title":"Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a\u00a0multicenter prospective registry","volume":"59","author":"Lakkireddy","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1253\/circj.CJ-12-0498","article-title":"Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation","volume":"76","author":"Kaseno","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2013.11.039_bib13","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hrthm.2012.12.011","article-title":"Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation","volume":"10","author":"Kim","year":"2013","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2013.11.039_bib14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/CIRCEP.113.000320","article-title":"Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation","volume":"6","author":"Bassiouny","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40261-013-0081-1","article-title":"Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation","volume":"33","author":"Yamaji","year":"2013","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.jacc.2013.11.039_bib16","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.039_bib17","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/europace\/eut128","article-title":"Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation","volume":"15","author":"Eitel","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2013.11.039_bib18","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib19","unstructured":"US Food and Drug Administration. FDA Access Data. December 2011. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202439s001lbl.pdf. Accessed January 20, 2014."},{"key":"10.1016\/j.jacc.2013.11.039_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1161\/CIRCULATIONAHA.109.928903","article-title":"Left atrial appendage: an underrecognized trigger site of atrial fibrillation","volume":"122","author":"Di Biase","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.039_bib21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.hrthm.2006.10.034","article-title":"How to recognize, manage, and prevent complications during atrial fibrillation ablation","volume":"4","author":"Dixit","year":"2007","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2013.11.039_bib22","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.110.937953","article-title":"Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation","volume":"122","author":"Gaita","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.039_bib23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10840-007-9200-3","article-title":"Atrial fibrillation ablation complications","volume":"22","author":"Sra","year":"2008","journal-title":"J\u00a0Interv Card Electrophysiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib24","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.jacc.2009.02.022","article-title":"Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation","volume":"53","author":"Cappato","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1253\/circj.CJ-08-1097","article-title":"Complications in the catheter ablation of atrial fibrillation: incidence and management","volume":"73","author":"Takahashi","year":"2009","journal-title":"Circ J"},{"key":"10.1016\/j.jacc.2013.11.039_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/HCO.0b013e32835b59bb","article-title":"How to ablate long-standing persistent atrial fibrillation?","volume":"28","author":"Di Biase","year":"2013","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib27","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/CIRCEP.109.859116","article-title":"Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation","volume":"3","author":"Cappato","year":"2010","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11936-013-0242-9","article-title":"Optimal strategies including use of newer anticoagulants for prevention of stroke and bleeding complications before, during, and after catheter ablation of atrial fibrillation and atrial flutter","volume":"15","author":"Bhave","year":"2013","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jacc.2013.11.039_bib29","doi-asserted-by":"crossref","first-page":"837841","DOI":"10.4061\/2011\/837841","article-title":"Atrial fibrillation ablation without interruption of anticoagulation","volume":"2011","author":"Santangeli","year":"2011","journal-title":"Cardiol Res Pract"},{"key":"10.1016\/j.jacc.2013.11.039_bib30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/pace.12036","article-title":"A\u00a0randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation","volume":"36","author":"Nin","year":"2013","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib31","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1540-8167.2011.02175.x","article-title":"The use of dabigatran immediately after atrial fibrillation ablation","volume":"23","author":"Winkle","year":"2012","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib32","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2012.04.052","article-title":"Safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing ablation for atrial fibrillation","volume":"60","author":"Lakkireddy","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.039_bib33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2013.11.039_bib34","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1185\/03007990802361499","article-title":"Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects","volume":"24","author":"Kubitza","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacc.2013.11.039_bib35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1160\/TH07-12-0714","article-title":"Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement","volume":"100","author":"Mueck","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2013.11.039_bib36","first-page":"126","article-title":"Rivaroxaban and its effect on international normalised ratio-a prospective study of 28 hip and knee arthroplasty patients","volume":"3","author":"Yeo","year":"2012","journal-title":"Am Med J"},{"key":"10.1016\/j.jacc.2013.11.039_bib37","unstructured":"A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (VENTURE-AF). Clinical Trials. 2012. Available at: http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01729871?term=rivaroxaban+atrial+fibrillation&rank=11. Accessed January 20, 2014."},{"key":"10.1016\/j.jacc.2013.11.039_bib38","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713065431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713065431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:05:29Z","timestamp":1760015129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713065431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0735109713065431"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.11.039","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and Safety of Uninterrupted Rivaroxaban for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}